Four Patients Die in Xarelto Study of 1,000, Notes Rottenstein Law Group LLP

The results of a recently-concluded study purport to show that Xarelto (rivaroxaban) is as safe as warfarin for patients atrial fibrillation patients awaiting elective cardioversion, even though four persons included in the study died.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Two patients out of nearly 1,000 might be only a fraction of a percent, but even a fraction of a percent of the millions of patients who are prescribed Xarelto is still thousands of people at risk

Rockville Centre, NY (PRWEB) September 04, 2014

According to an article published on September 2 at medpagetoday.com, atrial fibrillation patients awaiting elective cardioversion who had their oral anticoagulant switched from warfarin to Xarelto “were half as likely to have a stroke or a heart attack during cardioversion.”* The study was published The study—“Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation,” R. Cappato, et al.— was published online in the European Heart Journal.**

“The study mentions that four patients in the Xarelto group died—versus two patients in the ‘control’ group,” said Rochelle Rottenstein, principal of the Rottenstein Law Group, “which is supposedly a difference that is ‘not statistically significant.’ Two patients out of nearly 1,000 might be only a fraction of a percent, but even a fraction of a percent of the millions of patients who are prescribed Xarelto is still thousands of people.”

In 2013, the U.S. FDA received several hundred adverse event reports submitted by individuals who claimed to have a serious adverse side effect while taking Xarelto (rivaroxaban).** Data show that the number of persons being prescribed these blood thinning drugs is estimated at about 4 million for the year.** Anticoagulants (or “blood thinners”) are considered high-risk prescription drugs because they can cause excessive internal bleeding and other injuries in some patients.

Anyone needing more information about the potential dangers of Xarelto should visit the firm’s Xarelto page at http://www.rotlaw.com/xarelto. Representatives of the firm are available to answer any questions, and there is a confidential, no-cost claim evaluation form that can be filled out in order to determine if one has grounds to file a Xarelto lawsuit.

*http://www.medpagetoday.com/MeetingCoverage/ESC/47466
**http://eurheartj.oxfordjournals.org/content/early/2014/08/28/eurheartj.ehu367.full
***http://www.ismp.org/quarterwatch/pdfs/2013Q1.pdf

ABOUT THE ROTTENSTEIN LAW GROUP LLP
The Rottenstein Law Group LLP is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and medications. (Attorney advertising. Prior results do not guarantee a similar outcome.)

Contact:
The Rottenstein Law Group LLP
Rochelle Rottenstein, Esq.
100 Merrick Road
Suite 226W
Rockville Centre, NY 11570
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle (at) rotlaw (dot) com